Pavblu (aflibercept-ayyh)

Where it stands

The records list Pavblu (aflibercept-ayyh), from Amgen Inc, as approved in the US. The single milestone is an FDA approval dated 2026-10-22, filed under BLA761298. The record describes the product as a biosimilar in an injectable presentation, and the source is marked official.

The records leave several fields blank: therapeutic area, indication, and CHMP opinion date. Because the CHMP field is empty, the records show no EU opinion for this product. The approved indications, dosing and presentations therefore cannot be stated from this dataset and should be confirmed in the FDA-approved prescribing information.

Regulatory pathway and designations

The only designation recorded is Biosimilar. In general, a US biosimilar is approved through a BLA that relies on a demonstration of biosimilarity to an FDA-licensed reference product, rather than a full stand-alone development program. The records do not name the reference product or describe the data package, so they do not show which studies supported the approval.

The nonproprietary name carries the four-letter suffix "-ayyh", which follows the FDA convention of giving biological products a distinguishing suffix. The records say nothing about whether Pavblu has an interchangeability designation. That status, which affects pharmacy-level substitution under state law, should not be assumed and must be checked against the FDA's Purple Book or the label.

The record shows no orphan, fast track, priority review or other expedited designations. It also gives no PDUFA or BsUFA goal date or submission date, so review timing cannot be assessed from this data.

Safety and pharmacovigilance

The records contain no safety information: no boxed warning, adverse event profile, risk management requirements or postmarketing commitments. This analysis therefore draws no conclusions on the product's safety.

As general procedure, an approved biosimilar is subject to the same postmarketing safety reporting obligations as other biologics. Professionals tracking this product should review the approved label and FDA postmarketing surveillance sources for product-specific details.

What to watch

The records do not cover forward-looking events. These items would need to be verified from the label and other sources, not from this dataset:

- the approved indications and presentations; - the interchangeability status; - the reference product and any related patent or exclusivity position; - the commercial launch timing.

The approval date in the record is 2026-10-22. Users should confirm it against the FDA's own approval documentation before relying on it for timelines or competitive tracking. The EU position is also unrecorded, since there is no CHMP opinion date.